(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -36.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Entrada Therapeutics's revenue in 2025 is $172,220,000.On average, 3 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,670,443,742, with the lowest TRDA revenue forecast at $1,292,693,383, and the highest TRDA revenue forecast at $2,141,331,787. On average, 3 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,276,752,948, with the lowest TRDA revenue forecast at $170,790,377, and the highest TRDA revenue forecast at $2,141,331,787.
In 2027, TRDA is forecast to generate $2,141,331,787 in revenue, with the lowest revenue forecast at $2,141,331,787 and the highest revenue forecast at $2,141,331,787.